U.S., March 26 -- ClinicalTrials.gov registry received information related to the study (NCT07493551) titled 'A Bioequivalence Study of PP3M in Patients With Schizophrenia' on March 04.
Brief Summary: To evaluate the bioequivalence of the test formulation paliperidone palmitate injection (3M) produced by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. and the reference formulation paliperidone palmitate injection (3M) (brand name: Invega Trinza) by Janssen Pharmaceutica N.V. under multiple-dose administration.
Study Start Date: Oct. 09, 2024
Study Type: INTERVENTIONAL
Condition:
Schizophrenia
Intervention:
DRUG: Paliperidone Palmitate Injection (3M)
Intramuscular injection
Recruitment Status: RECRUITING
Sponsor: CSPC Zhongnu...